Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06173661 · ClinicalTrials.gov registry record · Phase 4
Fremanezumab Treatment of Migraine in Women With Menstrual Migraine Ages 18-45
A Phase 4 study of Migraine and Menstrual Migraine, sponsored by Brigham and Women's Hospital.
- Active
- Registry status
- Phase 4
- Development phase
- 72
- Enrollment target
- 1
- Study location
NCT06173661: Active Phase 4 study of Migraine and Menstrual Migraine, sponsored by Brigham and Women's Hospital.
NCT06173661 is a Phase 4 study of Migraine and Menstrual Migraine that is active but no longer recruiting, run by Brigham and Women's Hospital. The registered enrollment target is 72 participants, below the 358-participant average among 102 other Migraine trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06173661, a Phase 4 study of Migraine and Menstrual Migraine, is active but no longer recruiting, sponsored by Brigham and Women's Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 72 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to learn about how a migraine prevention medicine works for people who have migraines/headaches with their menstrual period. The study includes people ages 18 to 45 who have been diagnosed with migraine and who have a migraine with their menstrual period or those who have migraines with their menstrual period and at other times of the month as well. The main question the study aims to answer are: • Does fremanazemab, an injectable calcitonin gene-related peptide (CGRP) pathway targeting therapy, decrease migraines associated with menstruation? Participants will * have an evaluation and examination by a headache specialist physician * will receive the study medicine or inactive substitute every three months for two treatments * fill out diaries about their migraines * have tests on saliva to measure hormone levels Researchers will compare the people who get the medicine to those who get the inactive substitute to see if there are differences in response.
Primary Outcome
The number of active migraine days during the 24-week treatment period after the 1st dose of study drug.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Fremanezumab
Study Locations (1)
Massachusetts
- Brigham and Women's Health Care Center - Chestnut Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2024-03-01 |
| Est. Completion | 2026-07 |
| Phase | Phase 4 |
What the registry record for NCT06173661 still lists
NCT06173661 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 72 participants, a relatively small participant target, below the 358-participant average among 102 other Migraine trials with a reported enrollment target (80% lower).
The record links to 3 conditions, with Migraine appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06173661 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06173661 about?
NCT06173661 is a clinical study titled "Fremanezumab Treatment of Migraine in Women With Menstrual Migraine Ages 18-45". The goal of this clinical trial is to learn about how a migraine prevention medicine works for people who have migraines/headaches with their menstrual period. The study includes people ages 18 to 45 who have been diagnosed with migraine and who have a migraine with their menstrual period or those w...
What is the current status of trial NCT06173661?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 72 participants. The study started on 2024-03-01. Estimated completion is 2026-07.
What conditions does trial NCT06173661 study?
This clinical trial studies the following conditions: Migraine, Menstrual Migraine, Menstrually Related Migraine.
What interventions are being tested in trial NCT06173661?
The interventions under investigation include: Placebo (OTHER), Fremanezumab (DRUG).
Who is sponsoring clinical trial NCT06173661?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06173661 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06173661's enrollment target sits among peer trials
72 70th of 102 higher than 33 of 102 other Migraine trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Migraine trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Comparison of Nurtec ODT to Maxalt MLT-ODT in Adult ED Patients With Migraine Headache
RECRUITING · Phase 4
-
Effectiveness and Tolerability of Zavegepant for Acute Migraine Treatment Among Those Using CGRP Targeting Preventive Medications
RECRUITING · Phase 4
-
Rimegepant as Preemptive Treatment for Predictable Trigger-Induced Migraine in Adult Patients in the US
RECRUITING · Phase 4
-
Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study
RECRUITING · Phase 4
-
Nerivio Efficacy Under High-Frequency Use
ACTIVE NOT RECRUITING · Phase 4
-
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications
ACTIVE NOT RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02359253 · 72 participants · NA
Robot Aided Rehabilitation - Intervention
- NCT02962661 · 72 participants · Phase 1
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
- NCT03113643 · 72 participants · Phase 1
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- NCT03187535 · 72 participants · NA
Effect of TEAS on PONV After Spinal Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI